We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
151
AnaptysBio
ANAB
$1.59B
– –
-3,295
Closed -$101K
APGE icon
152
Apogee Therapeutics
APGE
$10.1B
– –
-64,250
Closed -$4.05M
ARCT icon
153
Arcturus Therapeutics
ARCT
$169M
– –
-48,811
Closed -$900K
ARCT icon
154
PUT
Arcturus Therapeutics
ARCT
$169M
– –
-150,900
Closed -$2.78M
AUPH icon
155
PUT
Aurinia Pharmaceuticals
AUPH
$1.89B
– –
-700
Closed -$7.74K
BMY icon
156
CALL
Bristol-Myers Squibb
BMY
$134B
– –
-180,000
Closed -$8.12M
BMY icon
157
Bristol-Myers Squibb
BMY
$134B
– –
-130,000
Closed -$5.86M
CCCC icon
158
CALL
C4 Therapeutics
CCCC
$384M
– –
-140,700
Closed -$312K
COGT icon
159
CALL
Cogent Biosciences
COGT
$6.67B
– –
-200,000
Closed -$2.87M
CPRX
160
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-50,000
Closed -$985K
CTMX icon
161
CytomX Therapeutics
CTMX
$684M
– –
-185,286
Closed -$591K
FOLD
162
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-131,400
Closed -$1.04M
HRMY icon
163
CALL
Harmony Biosciences
HRMY
$2.06B
– –
-150,000
Closed -$4.13M
HRMY icon
164
PUT
Harmony Biosciences
HRMY
$2.06B
– –
-50,100
Closed -$1.38M
INCY icon
165
CALL
Incyte
INCY
$24.1B
– –
-100,000
Closed -$8.48M
JAZZ icon
166
Jazz Pharmaceuticals
JAZZ
$15.8B
– –
-23,140
Closed -$3.55M
JAZZ icon
167
PUT
Jazz Pharmaceuticals
JAZZ
$15.8B
– –
-50,000
Closed -$6.59M
KOD icon
168
PUT
Kodiak Sciences
KOD
$2.49B
– –
-1,100
Closed -$18K
LLY icon
169
PUT
Eli Lilly
LLY
$1,000B
– –
-10,000
Closed -$7.63M
DFTX
170
Definium Therapeutics
DFTX
$5.53B
– –
-105,891
Closed -$1.25M
MREO
171
PUT
Mereo BioPharma
MREO
$52.4M
– –
-39,400
Closed -$81.2K
MRNA icon
172
CALL
Moderna
MRNA
$22B
– –
-102,100
Closed -$2.64M
MRNA icon
173
Moderna
MRNA
$22B
– –
-20,000
Closed -$517K
MRNA icon
174
PUT
Moderna
MRNA
$22B
– –
-100,000
Closed -$2.58M
NBIX icon
175
Neurocrine Biosciences
NBIX
$16.8B
– –
-37,754
Closed -$5.3M
5 6
7
8 9

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.